RT @BenWestphalen: Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with mic…
RT @BenWestphalen: Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with mic…
RT @BenWestphalen: Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with mic…
COLORECTAL: retrospective biomarker studies of human samples suggest that ARID1A mutation may be associated with increased immunogenicity in microsatellite stable disease; the underlying mechanism is not clear. https://t.co/wZoAotwmeE
ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer https://t.co/IPzlFDLDvy
ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer https://t.co/SXPE1qfqNR
RT @BenWestphalen: Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with mic…
RT @BenWestphalen: Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with mic…
RT @BenWestphalen: Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with mic…
Note: ARID1A mutation may define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer https://t.co/Yrb7LVHpdJ
RT @BenWestphalen: Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with mic…
RT @BenWestphalen: Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with mic…
RT @eportacangen: In the end, cancer immunology will all be about the drivers (and the germline!) https://t.co/MM34vrnZqz
RT @BenWestphalen: Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with mic…
RT @eportacangen: In the end, cancer immunology will all be about the drivers (and the germline!) https://t.co/MM34vrnZqz
RT @BenWestphalen: Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with mic…
In the end, cancer immunology will all be about the drivers (and the germline!)
RT @BenWestphalen: Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with mic…
RT @BenWestphalen: Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with mic…
RT @BenWestphalen: Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with mic…
RT @BenWestphalen: Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with mic…
RT @BenWestphalen: Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with mic…
ARID1-mutated MSS CRC has a higher TMB and indel burden with increased immune activation.
ARID1A #mutation may define an #immunologically active subgroup in patients with microsatellite-stable colorectal #cancer https://t.co/jR5b6aPfGy
Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with microsatellite-stable #crcsm @OncoAlert 🚨 #PrecisionMedicine https://t.co/G0j0O8B4XJ
ARID1A mutation may define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer https://t.co/T55to7Bmoy